Supernus Pharmaceuticals (SUPN) Non Operating Investment Income (2012 - 2017)
Supernus Pharmaceuticals (SUPN) reported Non Operating Investment Income of $23000.0 for Q2 2017, down 81.3% year-over-year from $123000.0 in Q2 2016, and down 57.41% quarter-over-quarter from $54000.0 in Q1 2017.
Supernus Pharmaceuticals (SUPN) Non Operating Investment Income (2012 - 2017) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 6 years of Non Operating Investment Income data on file, last reported at $23000.0 in Q2 2017.
- Non Operating Investment Income for Q2 2017 came in at $23000.0, down 81.3% year-over-year; the trailing twelve-month figure through Dec 2017 was $77000.0 (down 82.81% YoY), and the FY2017 annual result was $76000.0, down 83.04% from the prior year.
- Non Operating Investment Income fell to $23000.0 in Q2 2017 per SUPN's latest filing, from $54000.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $760000.0 in Q3 2014 and troughed at -$8.6 million in Q2 2013.
- A 5-year average of -$545944.4 and a median of $100000.0 in 2016 frame the typical range for Non Operating Investment Income.
- The sharpest annual moves came in 2013 and 2016: Non Operating Investment Income plunged 5885.42% in 2013, then surged 12200.0% in 2016.
- A 5-year view of Non Operating Investment Income shows it stood at -$662000.0 in 2013, then soared by 204.83% to $694000.0 in 2014, then plunged by 81.7% to $127000.0 in 2015, then declined by 22.05% to $99000.0 in 2016, then tumbled by 76.77% to $23000.0 in 2017.
- Business Quant data shows SUPN's Non Operating Investment Income at $23000.0 in Q2 2017, $54000.0 in Q1 2017, and $99000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | Supernus Pharmaceuticals | 2.60 Bn | 2.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 23,000.00 |
| Jun 30, 2017 | 23,000.00 |
| Mar 31, 2017 | 54,000.00 |
| Mar 31, 2017 | 54,000.00 |
| Dec 31, 2016 | 99,000.00 |
| Dec 31, 2016 | 99,000.00 |
| Sep 30, 2016 | 125,000.00 |
| Sep 30, 2016 | 125,000.00 |
| Jun 30, 2016 | 123,000.00 |
| Jun 30, 2016 | 123,000.00 |
| Mar 31, 2016 | 101,000.00 |
| Mar 31, 2016 | 101,000.00 |
| Dec 31, 2015 | 127,000.00 |
| Dec 31, 2015 | 127,000.00 |
| Sep 30, 2015 | 114,000.00 |
| Sep 30, 2015 | 114,000.00 |
| Jun 30, 2015 | 1,000.00 |
| Jun 30, 2015 | 1,000.00 |
| Mar 31, 2015 | -49,000.00 |
| Mar 31, 2015 | -49,000.00 |